KRAS and colorectal carcinoma: Although KRAS mutations have historically been labeled as “undruggable”, the rapid evolution of therapeutic platforms—encompassing small molecules, RNA-based drugs, and immunotherapies—holds the potential to transform outcomes for patients with KRAS-mutant CRC.